Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions.
A line probe assay (INNO-LiPA HBV DR) detecting drug-resistant hepatitis B virus (HBV) strains was evaluated. Results concordant with sequence analysis were obtained with 48 of 56 serum samples from HBV-infected patients undergoing lamivudine therapy. In eight cases, additional minor subpopulations could be identified by the line probe assay.
Aberle
S W
SW
Institute of Virology, University of Vienna, Kinderspitalgasse 15, A-1095 Vienna, Austria. stephan.aberle@univie.ac.at
Kletzmayr
J
J
Watschinger
B
B
Schmied
B
B
Vetter
N
N
Puchhammer-Stöckl
E
E
D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004279:DNA, Viral / Q000032:analysis / Q000235:genetics; D004259:DNA-Directed DNA Polymerase / Q000235:genetics*; D004352:Drug Resistance, Microbial / Q000235:genetics; D006515:Hepatitis B virus / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000188:drug therapy / Q000821:virology; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects; D019259:Lamivudine / Q000494:pharmacology* / Q000627:therapeutic use; D009154:Mutation; D017422:Sequence Analysis, DNA
D000998:Antiviral Agents; D004279:DNA, Viral; D019259:Lamivudine; D004259:DNA-Directed DNA Polymerase